EpidStrategies’ scientists are recognized experts in the field of respiratory syncytial virus (RSV). Our RSV research program supported the newly-approved monoclonal antibody with our studies being cited by the CDC (https://www.cdc.gov/vaccines/acip/recs/grade/nirsevimab-season2-rsv-infants-children-etr.html ). Mina Suh, Naimisha Movva, Heidi Reichert, and Xiaohui Jiang, along with clinicians and industry leaders, are presenting two RSV studies at IDWeek on October 11-15, 2023.
- Seasonality of infant respiratory syncytial virus associated bronchiolitis around the US since the onset of COVID-19: Results from four US health systems 2016-2023 (Poster 1535431).
- Prevention of respiratory syncytial virus hospitalizations (RSVH) in US infants who paid through Medicaid would have a disproportionate benefit for Black, Hispanic, Asian/Pacific Islander, Native American and Other race/ethnicity infants, and have a substantial impact on overall RSVH burden and related costs: Rates of respiratory syncytial virus hospitalization (RSVH) among US infants by race/ethnicity and insurance payer, NIS 2018-2020 (Poster 1536169).
Please contact Mina Suh (msuh@epidstrategies.com) for more information.